| Status | Study |
| Not yet recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Condition: Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Adenoca Date: 2017-04-14 Interventions: Procedure: Biopsy Undergo imag |
| Not yet recruiting |
Study Name: Study to Evaluate Efficacy and Safety of Sunitinib in Patients With Renal Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment Condition: Clear Cell Renal Carcinoma Date: 2017-02-23 Interventions: Drug: Sunitinib Sunitinib 50 mg/d |
| Recruiting |
Study Name: A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors Condition: Advanced Solid Tumors Solid Tumor Solid Carcinoma Date: 2016-11-23 Interventions: Drug: PT2977 PT2977 is a highly selective small molecule that inhibits the function of the HIF-2α t |
| Recruiting |
Study Name: Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Condition: Breast Carcinoma Endometrial Clear Cell Adenocarcinoma Date: 2016-08-17 Interventions: Drug: Metformin Hydrochloride |
| Recruiting |
Study Name: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endomet Date: 2016-07-29 Interventions: Biological: Bevacizumab Given |
| Recruiting |
Study Name: Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Condition: Ovarian Clear Cell Carcinoma Endometrial Date: 2016-07-22 Interventions: Drug: Nintedanib Nintedanib (B |
| Not yet recruiting |
Study Name: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endomet Date: 2016-07-20 Interventions: Drug: Atezolizumab Given IV |
| Recruiting |
Study Name: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endomet Date: 2016-03-15 Interventions: Drug: Carboplatin Given IV |
| Recruiting |
Study Name: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Condition: Renal Clear Cell Carcinoma Renal Papillary Cell Carcinoma Date: 2016-02-22 Interventions: Drug: Savolitinib Other Names: |
| Recruiting |
Study Name: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Date: 2015-07-17 Interventions: Drug: Cediranib Maleate Given |